Pancreatic intraductal neoplasms are growths inside the ducts of the pancreas. These growths can sometimes become cancerous. Doctors need to monitor these growths carefully.
Every report comes from a Lived member, sent anonymously.
Have you had Whipple Procedure for Pancreatic Intraductal Tumors?
Pancreatic intraductal tumors are growths that start in the cells lining the pancreatic ducts, the small tubes that carry digestive juices through the pancreas, and grow inside those ducts. They are not cancer when they first form, but some can slowly change into pancreatic cancer over years. That is why they are watched closely or removed. By far the most common type is an intraductal papillary mucinous neoplasm (IPMN). Its cells make thick mucus, which stretches the duct into a fluid-filled pouch, so an IPMN usually shows up on a scan as a pancreatic cyst. Most IPMNs cause no symptoms and are found by chance on a CT or MRI done for another reason, especially in people over 65. They are considered precancerous, and many never become cancer. Where an IPMN sits matters. A branch-duct IPMN grows in the small side branches of the pancreatic duct and carries the lowest risk. A main-duct IPMN, or a mixed type that involves both, affects the central duct and is much more likely to contain advanced precancerous change or cancer. A much rarer type, the intraductal tubulopapillary neoplasm (ITPN), makes little mucus and instead forms a solid plug inside the duct. ITPNs usually already show advanced changes when found and are generally treated with surgery.
These tumors develop when genes that control cell growth in the duct lining change during a person's life. In most people no specific reason for those changes can be identified, and nothing the person did is known to have caused them. IPMNs become more common with age. A family history of pancreatic cancer is linked to a higher chance of having an IPMN and, after surgery, to a higher chance of new disease in the remaining pancreas. Smoking, heavy drinking and diabetes are recognized risk factors for pancreatic cancer in general, so they are often discussed in IPMN care too, but they are not known to cause an IPMN directly. Part of the reason IPMNs seem more common now is simply that more people have detailed scans. Many small cysts that would once have gone unnoticed are now seen.
The main test is an MRI of the abdomen with MRCP (magnetic resonance cholangiopancreatography), a type of MRI that shows the pancreatic and bile ducts in detail. A CT scan is used when MRI is not possible. These scans show where the cyst is, whether it connects to the duct system, how wide the main pancreatic duct is, and whether there is any solid tissue. The point of testing is to sort a cyst into lower or higher risk. Features that raise concern include a solid lump (often called a mural nodule) inside the cyst, a main pancreatic duct wider than normal, a cyst that is growing quickly or is larger than about 3 centimeters, new or suddenly worsening diabetes, and episodes of pancreatitis. A main duct 10 millimeters or wider, a solid nodule 5 millimeters or larger, or yellowing of the skin and eyes (jaundice) from a blocked bile duct are treated as high-risk signs. No single feature proves cancer; clinicians weigh the whole picture. When features are unclear, an endoscopic ultrasound may follow. A thin scope passed through the mouth into the stomach lets the doctor see the pancreas up close and, if needed, draw out cyst fluid or cells with a fine needle for testing. A blood test called CA 19-9 is sometimes checked, but it is not reliable enough to decide on its own.
Treatment depends on the type of tumor, its risk features and the person's overall health. The aim is to remove tumors that are likely to become cancer before they do, while sparing people with low-risk cysts from an operation they may never need. Most branch-duct IPMNs without concerning features are managed with surveillance: repeat MRI or CT scans at intervals set by the cyst's size and stability. A large cohort study found that only a small share of these cysts develop worrying features over about five years, and around 1 percent develop pancreatic cancer in that time. For small cysts that stay unchanged for five years, current international guidelines allow either stopping surveillance or continuing it, partly because pancreatic cancer can still arise elsewhere in the pancreas. Surgery is considered for main-duct IPMNs with a clearly widened duct (10 millimeters or more), for cysts with other high-risk features, and for ITPNs, in people well enough for a major operation. The operation depends on location: a Whipple procedure (pancreaticoduodenectomy) for the head of the pancreas, a distal pancreatectomy for the body or tail, and occasionally removal of the whole pancreas when the disease runs throughout it. These are major operations. Complications are common, including leaks of pancreatic fluid, and in experienced centers about 1 to 3 percent of people die after a Whipple procedure and under 1 percent after a distal pancreatectomy. Removing part of the pancreas can lead to diabetes or to needing digestive enzyme capsules with meals; removing all of it causes both permanently. That trade-off is why age, other illnesses and personal preferences shape the decision. For an older or frail person with a cyst that has only moderate warning features, cancer may take many years to develop or may never develop, and surveillance can be the more sensible choice. When an IPMN or ITPN has already become invasive cancer, treatment follows pancreatic cancer care and may include chemotherapy after surgery.
For most people with a small branch-duct IPMN, daily life does not change. The main commitment is regular imaging, usually MRI, and perhaps occasional visits with a gastroenterologist or pancreatic surgeon. Many cysts stay stable for years. Living with a known precancerous growth can cause worry, and it is reasonable to ask the care team how low your own risk is and what would change the plan. After surgery, recovery from a Whipple procedure or distal pancreatectomy usually involves several days in the hospital and some weeks of recovery at home. Some people need digestive enzymes with meals or treatment for diabetes afterward. Surveillance does not end with the operation: new IPMNs or cancer can appear in the remaining pancreas, so follow-up scans continue, more often when the removed tumor had high-grade change or cancer. Outlook depends mainly on whether cancer had developed. When an IPMN is removed before it becomes invasive cancer, about 95 percent of people are alive five years later. ITPN with an invasive component generally has a better outlook than ordinary pancreatic cancer, though experience with this rare tumor is limited.
If a scan has found a pancreatic cyst, arrange a visit with a gastroenterologist or pancreas specialist to decide whether it needs surveillance or further testing, and keep up with scheduled scans. Contact your care team within a week or two, rather than waiting for your next scheduled scan or visit, if you develop new diabetes or diabetes that suddenly becomes harder to control, unexplained weight loss, or oily, foul-smelling stools, since these can signal a change in the pancreas that needs earlier testing. Contact your care team promptly, the same day, for yellowing of the skin or the whites of the eyes. Severe or worsening upper abdominal pain, especially pain that spreads to the back with vomiting, fever or a racing heartbeat, can be acute pancreatitis and needs urgent medical care right away.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Pancreatic Intraductal Tumors is like, what's helped you, or ask the community a question.